GlycoErase™ XYLT1 Knockout Human Glioma Cell A172 (CAT#: GLJF-0525-JF876)

Description	The XYLT1 knockout A172 cell line, deficient in a protein involved in glycosaminoglycan biosynthesis, enables the investigation of how glycosaminoglycan disruption affects glioma, influencing cell-matrix interactions and immune functions within the tumor microenvironment.
Product Type	KO Cell Lines
Species	Human
Cell Morphology	Epithelial-like, adherent
Passage Ratio	1:2~1:3
Cell Line	A172
Primary Disease	Diffuse Glioma
Lineage	CNS/Brain

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Culture Medium	DMEM & FBS & Glutamine
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	XYLT1
Full Name	Xylosyltransferase 1
Alternative Name	XT-I, PXYLT1
Location	64131
Gene ID	64131
Summary	Catalyzes the transfer of UDP-xylose to serine residues, initiating the biosynthesis of glycosaminoglycan chains.